This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ALGN Stock Might Rise Following the NMPA Approval in China
by Zacks Equity Research
Align Technology receives approval from the National Medical Products Administration in China for its Invisalign Palatal Expander System.
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
by Nalak Das
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Top Health & Fitness Stocks to Buy for the Wellness Boom
by Nilanjan Choudhury
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx
by Zacks Equity Research
Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx are included in this Analyst Blog.
QIAGEN Stock Gains Following the Acquisition of Genoox
by Zacks Equity Research
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
by Nalak Das
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
5 Best Stocks of the S&P 500 ETF in the Past Month
by Sweta Killa
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Q1 Earnings Miss Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -3.03% and 1.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for DexCom (DXCM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
by Zacks Equity Research
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
by Zacks Equity Research
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
by Zacks Equity Research
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
by Zacks Equity Research
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
by Zacks Equity Research
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic
by Zacks Equity Research
AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
by Urmimala Biswas
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.